C07K 14/4738
Cell cycle regulated proteins
Official title: {Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR (cell cycle dependent kinases C12N9/12)}
C07K14/4738 (Cell cycle regulated proteins) appears on 340 US grants and 355 published applications in this corpus.
Search patents in C07K- Granted patents
- 340
- Published applications
- 355
- Assignees
- 242
- Inventors
- 751
- Latest grant
- 25 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1995 | 2 | 0 |
| 1996 | 2 | 0 |
| 1997 | 9 | 0 |
| 1998 | 15 | 0 |
| 1999 | 24 | 0 |
| 2000 | 22 | 0 |
| 2001 | 21 | 1 |
| 2002 | 24 | 23 |
| 2003 | 24 | 40 |
| 2004 | 9 | 23 |
| 2005 | 12 | 16 |
| 2006 | 10 | 9 |
| 2007 | 8 | 20 |
| 2008 | 9 | 15 |
| 2009 | 12 | 5 |
| 2010 | 10 | 13 |
| 2011 | 10 | 16 |
| 2012 | 4 | 8 |
| 2013 | 5 | 10 |
| 2014 | 8 | 13 |
| 2015 | 9 | 14 |
| 2016 | 11 | 15 |
| 2017 | 10 | 20 |
| 2018 | 9 | 13 |
| 2019 | 16 | 14 |
| 2020 | 10 | 12 |
| 2021 | 9 | 13 |
| 2022 | 11 | 20 |
| 2023 | 1 | 11 |
| 2024 | 7 | 2 |
| 2025 | 1 | 5 |
| 2026 | 6 | 4 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Pharmaceutical composition for lowering blood cholesterol, preventing or treating cardiovascular diseases and reducing inflammation25 Aug 2026US 12,715,899 B2Seoul National University Hospital
- Sliding clamp-based affinity purification systems, methods of making and use thereof24 Mar 2026US 12,583,886 B2King Abdullah University of Science and Technology
- Methods and compositions relating to chimeric antigen receptors17 Mar 2026US 12,577,288 B2Trustees of Boston University
- Cyclin A1 specific T cell receptors and uses thereof10 Mar 2026US 12,570,712 B2Fred Hutchinson Cancer Center
- Inhibitors of cyclin-dependent kinases3 Feb 2026US RE50,776 E1Dana-Farber Cancer Institute, Inc.
- Modulation of b-cell translocation gene 1 (btg1) for use in adoptive cell therapy1 Oct 2026US 2026/0294968 A1Baylor College of Medicine
- Novel alk and ntrk1 fusion molecules and uses thereof2 Jul 2026US 2026/0185165 A1Foundation Medicine, Inc.
- Methods and compositions relating to chimeric antigen receptors11 Jun 2026US 2026/0159567 A1Trustees of Boston University
- Combination cancer therapy14 May 2026US 2026/0131028 A1Delta Next-Gene, LLC
- Peptides and engineered t cell receptors targeting ndc80 antigen and methods of use18 Sep 2025US 2025/0289866 A1Board of Regents, The University of Texas System
Most cited
By later US patents
- Methods for determining isolated p27 protein levels and uses thereof115US 6,316,208 B1Fred Hutchinson Cancer Research Center · 2001
- Methods for the activation of proliferation of animal cells91US 5,811,299 A1998
- Mammalian cell cycle protein91US 6,291,642 B1Amgen Inc. · 2001
- Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer84US 7,919,467 B2Immunotope, Inc. · 2011
- Method for diagnosing neoplasia by detecting expression of PRAD1 cyclin80US 5,858,655 AThe General Hospital Corporation · 1999